These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 28283926

  • 1. Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.
    Marketou M, Gupta Y, Jain S, Vardas P.
    Curr Hypertens Rep; 2017 Mar; 19(3):22. PubMed ID: 28283926
    [Abstract] [Full Text] [Related]

  • 2. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E, Rizzoni D.
    Drugs; 2007 Mar; 67(8):1097-107. PubMed ID: 17521213
    [Abstract] [Full Text] [Related]

  • 3. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L.
    Drugs; 2010 Mar; 70(1):41-56. PubMed ID: 20030424
    [Abstract] [Full Text] [Related]

  • 4. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D, Papademetriou V.
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
    [Abstract] [Full Text] [Related]

  • 5. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes.
    Fogari R, Zoppi A, Lazzari P, Mugellini A, Lusardi P, Preti P, Van Nueten L, Vertommen C.
    J Hum Hypertens; 1997 Nov; 11(11):753-7. PubMed ID: 9416986
    [Abstract] [Full Text] [Related]

  • 6. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM, Antonucci G, Conte M, Di Pumpo M, Giancola A, Antonucci E.
    Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394
    [Abstract] [Full Text] [Related]

  • 7. The role of nebivolol in the management of hypertensive patients: from pharmacological profile to treatment guidelines.
    Ferri C.
    Future Cardiol; 2021 Nov; 17(8):1421-1433. PubMed ID: 34060323
    [Abstract] [Full Text] [Related]

  • 8. A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension.
    Cicero AFG, Kuwabara M, Borghi C.
    Drugs; 2018 Nov; 78(17):1783-1790. PubMed ID: 30426333
    [Abstract] [Full Text] [Related]

  • 9. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients.
    Poirier L, Cléroux J, Nadeau A, Lacourcière Y.
    J Hypertens; 2001 Aug; 19(8):1429-35. PubMed ID: 11518851
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM, Fici F, Mascagni F.
    Am J Cardiovasc Drugs; 2008 Aug; 8(1):35-44. PubMed ID: 18303936
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men.
    Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH.
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):327-31. PubMed ID: 17324145
    [Abstract] [Full Text] [Related]

  • 13. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 14. Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage.
    Coats A, Jain S.
    J Hum Hypertens; 2017 Jun; 31(6):376-381. PubMed ID: 28252041
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.
    Ayers K, Byrne LM, DeMatteo A, Brown NJ.
    Hypertension; 2012 Apr; 59(4):893-8. PubMed ID: 22353614
    [Abstract] [Full Text] [Related]

  • 17. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J, Faülhaber HD.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():77-82. PubMed ID: 15700490
    [Abstract] [Full Text] [Related]

  • 18. What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?
    Pedersen ME, Cockcroft JR.
    Curr Opin Cardiol; 2009 Jul 27; 24(4):325-32. PubMed ID: 19417638
    [Abstract] [Full Text] [Related]

  • 19. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
    Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, Elisaf M, Mikhailidis DP.
    J Cardiovasc Pharmacol Ther; 2003 Jun 27; 8(2):127-34. PubMed ID: 12808486
    [Abstract] [Full Text] [Related]

  • 20. Nitric oxide mechanisms of nebivolol.
    Maffei A, Lembo G.
    Ther Adv Cardiovasc Dis; 2009 Aug 27; 3(4):317-27. PubMed ID: 19443516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.